Proactive - Interviews for investors

Custom Health reports 70% revenue growth, expands U.S. footprint through acquisitions

Episode Summary

Custom Health CEO Shane Bishop joined Steve Darling from to discuss the company's fiscal second-quarter 2026 results, highlighting strong revenue growth, strategic acquisitions and continued expansion of its medication management platform. Bishop said the quarter was marked by the company's successful TSX listing, the integration of InnovativeRx, and continued efforts to build a comprehensive at-home healthcare platform. He added that proposed acquisitions of Evergreen Pharmacy and Spencer Health Solutions are expected to further strengthen the company's pharmacy network and in-home technology capabilities. For the quarter ended June 30, 2026, Custom Health reported revenue of US$7.4 million, up 70% from US$4.3 million a year earlier. Gross profit increased 43% to US$2.9 million, while gross margin was 39.3% compared to 46.7% in the prior-year period. The company reported an adjusted EBITDA loss of US$3.3 million, compared to a loss of US$3.0 million in the same quarter last year. Net loss from continuing operations was US$33.4 million, largely due to a one-time, non-cash IFRS listing expense of US$22.4 million related to the company's reverse takeover transaction. Chief Financial Officer Jason Nalewany said the company expects to exceed US$130 million in annualized revenue run rate by year-end and achieve positive EBITDA in 2027, assuming the completion and integration of its planned acquisitions. During the quarter, Custom Health completed the acquisition of substantially all operating assets of InnovativeRx for approximately US$16.6 million, expanding its presence across Indiana and Ohio. The company also completed its transformation from Queue Ventures Ltd. to Custom Health Holdings Inc. and began trading on the Toronto Stock Exchange under the symbol CHLT. #proactiveinvestors #customhealth #tsx #nhlt #pharma #DigitalHealth #ConnectedCare #HealthcareTechnology #Pharmacy #Telehealth #TSX #HealthTech #PatientCare #HealthcareInnovation #DigitalHealth #SpecialtyPharmacy #HealthTech #TSX #Acquisitions #PatientCare #HealthcareInnovation